Hortobagyi G.N., Theriault R.L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler
H., Simeone J.F., Seaman J., Knight R.D.
Efficacy of pamidronate in reducing skeletal
complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia
Breast Cancer Study Group [see comments] // The N. Engl. J. Med. 1996.
V. 335(24). P. 1785 1791.
Hortobagyi G.
New cytotoxic agents for the treatment of breast cancer // Oncology.
1996. V. 10(suppl 6). P. 21 29.
Hortobagyi G.N., Theriault R.L., G.N., Lipton A.,
่ ๑๎เโ๒. Long term prevention of
skeletal complications of metastatic breast cancer with pamidronate // Protocol 19 Aredia
Breast Cancer Study Group. 1998. V. 16. P. 2038 2044.
Horton Y.
Follow up of breast cancer patients // Cancer. 1984. V. 53.
น 3. P. 790 797.
Hoskin P.J.
Palliation of bone metastases // Eur. J. Cancer. 1991. V. 27.
P. 950 951.
Houston S.J., Rubens R.D.
The systemic treatment of bone metastases // Clin.
Orthop. 1995. V.312. P. 95 104.
Howell A., Mackintosh J., Jones M.
่ ๑๎เโ๒. The definition of the no change cat
egory in patients treated with endocrine therapy and chemotherapy for advanced carcino
ma of the breast // Eur. J. Cancer Clin. Oncol. 1988. V. 24. P.1567 1572.
Howell A., DeFriend D., Robertson J.,
่ ๑๎เโ๒. Response to a specific antioestrogen
(ICI 182,780) in tamoxifen resistant breast cancer // Lancet. 1995. V. 345. P. 29
30.
Huffer W.E.
Morphology and biochemistry of bone remodelling: possible control by
vitamin D, parathyroid hormone, and other substances // Lab. Invest. 1988. V. 59.
P. 418 442.
Huggia F.M.
Overview of cancer related hypercalcaemia: epidemiology and etiology
// Semin. Oncol. 1990. V. 17. P. 3 9.
Ikeda K., Mangin M., Dreyer B.
่ ๑๎เโ๒. Identification of transcripts encoding a
parathyroid hormone like peptide in messenger RNA
,
s from a variety of human an animal
tumors associated with hypercalcaemia of malignancy // J. Clin. Invest. 1988. V. 81.
P. 2010 2014.
Ingle J.M.
Bone marrow involvement in breast cancer: effect on response and toler
ance to combination chemotherapy // Cancer. 1977. V. 39. P. 104 111.
Ingle J.M., Tormey D.C., Tan H.K.
The bone marrow examination in breast cancer.
Diagnostic considerations and clinical usefulness // Cancer. 1978. V. 41. P. 670
674.
Ingle J.N., Green S.J., Ahman D.L., Edmonson J.H., Nichols W.C., Frytak S., Rubin
J.
Progress report of two clinical trials in women with advanced breast cancer. Trial I:
tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in
patients with prior tamoxifen exposure // Cancer Res. Aug. V. 42 (Suppl. 8). 1982.
P.3461 3467.
Ingle J.N.
Principles of therapy in advanced breast cancer// Hematol. Oncol. Clin.
North. Am. 1989. V. 3(4). P.743 63.
Irwin L.
Randomized comparison of two combination chemotherapy regimens con
taining adriamycin in patients with metastatic breast cancer // Cancer Treat. Rep.
1980. in press.
Isales C., Carcangui M.L., Stewart A.F.
Hypercalcaemia in breast cancer: a re eval
uation // Am. J. Med. 1987. V. 82. P. 1143 1147.
231
ส๎๑๒ํ๛ๅ ์ๅ๒เ๑๒เ็๛ ๐เ๊เ ์๎๋๎๗ํ๎้ ๆๅ๋ๅ็๛
